UNIVEST FINANCIAL Corp Has $40.56 Million Stake in Eli Lilly and Company $LLY

Key Points

• UNIVEST FINANCIAL Corp increased its Eli Lilly stake by 4.2% in the second quarter to 33,820 shares valued at approximately $40.56 million, making LLY its 13th-largest holding. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with earnings of $8.38 per share and revenue of $22.97 billion, up 47.7% year over year and well above analyst expectations. Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $1,292.18.
• Lilly’s growth prospects remain tied to its obesity-treatment momentum, RNA vaccine collaboration and expanding clinical pipeline, but the company faces competition from Novo Nordisk in oral GLP-1 drugs. Insiders sold 13,500 shares worth about $15.96 million over the past three months through pre-arranged trading plans.

UNIVEST FINANCIAL Corp raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,820 shares of the company's stock after purchasing an additional 1,375 shares during the period. Eli Lilly and Company accounts for approximately 2.0% of UNIVEST FINANCIAL Corp's investment portfolio, making the stock its 13th biggest position. UNIVEST FINANCIAL Corp's holdings in Eli Lilly and Company were worth $40,565,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Mosaic Family Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Generali Investments Management Co LLC boosted its position in shares of Eli Lilly and Company by 17.5% during the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock valued at $12,258,000 after buying an additional 1,521 shares during the last quarter. Amundi grew its holdings in Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company's stock worth $4,649,464,000 after buying an additional 454,549 shares in the last quarter. Whitener Capital Management Inc. grew its holdings in Eli Lilly and Company by 79.3% during the second quarter. Whitener Capital Management Inc. now owns 2,960 shares of the company's stock worth $3,550,000 after buying an additional 1,309 shares in the last quarter. Finally, Moran Wealth Management LLC raised its position in Eli Lilly and Company by 85.6% in the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock valued at $25,072,000 after buying an additional 9,638 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based Chai Discovery on an RNA vaccine platform. The partnership could expand Lilly’s technology and early-stage pipeline, though the financial impact is likely to be longer term. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Recent coverage continues to highlight Lilly’s momentum in obesity treatment, with its products reportedly outpacing Novo Nordisk’s offerings. This reinforces expectations for sustained demand and supports LLY’s growth narrative. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Analyst-focused coverage identifies Eli Lilly as a leading candidate for significant earnings growth and a potential buy point as the broader market rebounds. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Neutral Sentiment: Lilly completed or advanced several clinical studies, including trials involving hidradenitis suppurativa, lebrikizumab, LY4178256 and eloralintide. The updates broaden the pipeline, but no decisive efficacy or regulatory results were provided. Lilly clinical-trial updates
• Neutral Sentiment: Discussion of a possible stock split reflects the sharp rise in LLY’s share price, but a split would not change the company’s fundamental value or earnings outlook. Stock Split Watch: Is Eli Lilly Stock Next?
• Negative Sentiment: Lilly continues to face competition from Novo Nordisk in the emerging oral GLP-1 market. The race creates substantial growth potential but also raises execution and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Insider Activity

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last three months. Company insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LLY shares. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Morgan Stanley reiterated an "overweight" rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday. Finally, Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,292.18.

Eli Lilly and Company Trading Up 0.1%

NYSE LLY opened at $1,257.26 on Monday. The stock has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.19, a PEG ratio of 1.48 and a beta of 0.51. Eli Lilly and Company has a one year low of $694.23 and a one year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The business's fifty day moving average is $1,180.14 and its 200-day moving average is $1,059.93.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is currently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source